Chengdu Kanghua Biological Products Co Ltd
300841
Company Profile
Business description
Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine.
Contact
No. 182, Beijing Road
Chengdu Economic and Technological Development Zone
Sichuan Province
Chengdu610100
CHNT: +86 2884846555
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
620
Stocks News & Analysis
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
With recent structural changes and strong Azure performance, here’s what we think of Microsoft stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,317.20 | 26.50 | -0.28% |
| CAC 40 | 8,225.63 | 0.15 | -0.00% |
| DAX 40 | 24,239.89 | 32.10 | 0.13% |
| Dow JONES (US) | 47,207.12 | 472.51 | 1.01% |
| FTSE 100 | 9,645.62 | 67.05 | 0.70% |
| HKSE | 26,160.15 | 192.17 | 0.74% |
| NASDAQ | 23,204.87 | 263.07 | 1.15% |
| Nikkei 225 | 49,299.65 | 658.04 | 1.35% |
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% |
| S&P 500 | 6,791.69 | 53.25 | 0.79% |
| S&P/ASX 200 | 9,019.00 | 25.20 | -0.28% |
| SSE Composite Index | 3,950.31 | 27.90 | 0.71% |